Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.66% | 196.94 | 1.3% | $565.97m | |
| GILD | Gilead Sciences, Inc. | 0.70% | 66.42 | 0.9% | $368.71m | |
| BIIB | Biogen Inc. | 1.35% | 238.79 | 1.3% | $340.32m | |
| ILMN | Illumina, Inc. | 1.43% | 309.57 | 3.5% | $338.07m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.62% | 106.32 | 2.0% | $332.28m | |
| CELG | Celgene Corporation | 0.42% | 99.37 | 1.3% | $309.99m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.40% | 295.87 | 2.6% | $188.33m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.12% | 178.12 | 1.9% | $186.01m | |
| A | Agilent Technologies, Inc. | -0.18% | 77.93 | 1.6% | $185.14m | |
| EXAS | Exact Sciences Corporation | 0.55% | 103.97 | 24.1% | $152.91m | |
| SRPT | Sarepta Therapeutics, Inc. | -3.34% | 82.51 | 14.6% | $139.60m | |
| ACAD | ACADIA Pharmaceuticals Inc. | -2.26% | 40.74 | 13.9% | $129.03m | |
| INCY | Incyte Corporation | 3.96% | 81.21 | 2.5% | $93.98m | |
| ALDR | Alder Biopharmaceuticals, Inc. | -0.11% | 18.64 | 10.2% | $81.98m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.38% | 74.95 | 4.3% | $76.08m |
Company Profile
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.